BioSpectrum Asia:
Shimadzu will support ChromaCode’s business and contribute to the development of cancer and infectious diseases testing technologies Japan-based Shimadzu Corporation has invested in ChromaCode Inc., a US-based startup with technology to expand genetic testing, through its corporate venture capital (CVC) fund, Shimadzu Future Innovation Fund L.P. (Shimadzu FIF). This is Shimadzu FIF’s first investment.
